&w=3840&q=100)
Sun Pharma's ILUMYA delivers positive psoriatic arthritis trial results
The Phase 3 INSPIRE-1 and INSPIRE-2 studies evaluated the efficacy and safety of ILUMYA over a 24-week period. According to the company, both trials achieved statistically significant improvements in ACR20 response rates—a standard measure of arthritis treatment effectiveness—compared with placebo at Week 24.
INSPIRE-1 included patients with prior exposure to anti-TNF therapies, while INSPIRE-2 focused on anti-TNF naïve patients. More than 800 adult participants were enrolled across clinical sites in the US, Europe, and Asia. ILUMYA was administered at Week 0 and every 12 weeks thereafter, with no induction dose.
Consistent safety profile supports regulatory case
Sun Pharma stated that the safety outcomes in the psoriatic arthritis trials were consistent with ILUMYA's established safety profile from earlier studies in plaque psoriasis. No new safety signals were identified.
ILUMYA is currently approved in the US and other countries for the treatment of moderate-to-severe plaque psoriasis in adults. Its use in psoriatic arthritis remains investigational and has not yet been evaluated by regulatory authorities.
Detailed results from the INSPIRE studies will be presented at upcoming medical conferences and submitted for publication in peer-reviewed journals.
Targeting IL-23 in chronic inflammatory pathways
ILUMYA is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), thereby inhibiting inflammatory pathways associated with chronic autoimmune conditions. Common adverse reactions reported in previous studies include upper respiratory infections, injection-site reactions, and diarrhoea. The drug carries warnings related to hypersensitivity, infections, and tuberculosis risk.
Psoriatic arthritis affects an estimated 2.4 million people in the United States. Approximately one-third of psoriasis patients may develop the joint condition, though many cases remain undiagnosed.
Strategic pipeline strengthens global presence
Sun Pharma is India's largest pharmaceutical company and one of the world's leading generic drug manufacturers. The company operates in over 100 countries and has a growing specialty portfolio in dermatology, ophthalmology, and onco-dermatology.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
25 minutes ago
- Time of India
Sudip Bandyopadhyay on 2 sectors offering ‘Trump-Proof' investment opportunities
Synopsis Indian infrastructure and capital goods sectors show promise. Tariff-related disruptions are creating uncertainty worldwide. Government spending benefits infrastructure and capital goods. Larsen & Toubro is a top pick. Diagnostics face margin pressure. Hospitals are consolidating with global investments. Sun Pharma and Mankind Pharma are appealing. These sectors are poised for growth. Investors should consider these factors.
Time of India
33 minutes ago
- Time of India
Neuro scans of adults in UK reveal faster ageing of brain post-pandemic
New Delhi: Experiencing the COVID-19 pandemic may have accelerated brain ageing by five and a half months, regardless of one's infection status, according to a new study, which researchers said point to the indirect effects of aspects such as isolation and uncertainty. The researchers, led by those from the University of Nottingham, analysed brain scans of adults in the UK taken before and after the pandemic. They found that changes were most noticeable among the brains of older individuals, men, and people from disadvantaged backgrounds, such as those unemployed and having lower incomes or education. However, brain ageing was found to impact cognitive function, with 'brain fog' and difficulty in focussing being common symptoms, only in those who were infected with COVID-19, suggesting that brain ageing alone may not necessarily produce symptoms. The findings, published in the journal Nature Communications, highlight "how much the experience of the pandemic itself, everything from isolation to uncertainty, may have affected our brain health," said lead researcher Ali-Reza Mohammadi-Nejad, research fellow at the university's faculty of medicine and health sciences. "What surprised me most was that even people who hadn't had Covid showed significant increases in brain ageing rates," Mohammadi-Nejad added. According to the authors, the pandemic-related brain ageing "may be at least partially reversible", but being strongly linked with socio-economic deprivation, the policies addressing inequalities are urgently needed, given that existing gaps widened during this time. AI-powered models which were used for predicting brain age were first trained on magnetic resonance image (MRI) brain scans of over 15,000 healthy people from the UK Biobank. The models thus learnt to measure the 'brain age gap' i.e. how much one's brain age differed from their actual age. The models were then employed to analyse two scans of the brains of 996 healthy participants, in 564 people (controls) both the scans were taken before the pandemic, while in the 'Pandemic' group consisting of 432 individuals, one scan was taken before and one after. "The 'Pandemic' group shows on average (a) 5.5-month higher deviation of brain age gap at the second time point, compared with controls," the authors wrote. They also found that "accelerated brain ageing is more pronounced in males and those from deprived socio-demographic backgrounds and these deviations exist regardless of SARS-CoV-2 (virus that causes COVID-19) infection." Further, cognitive tests taken at the time of both scans revealed that an "accelerated brain ageing correlates with reduced cognitive performance only in COVID-infected participants." Senior author Dorothee Auer, professor of neuroimaging at the University of Nottingham, said "This study reminds us that brain health is shaped not only by illness, but by our everyday environment." "The pandemic put a strain on people's lives, especially those already facing disadvantage. We can't yet test whether the changes we saw will reverse, but it's certainly possible, and that's an encouraging thought," Auer said.
Time of India
2 hours ago
- Time of India
Govt greenlights 10 new reactors; 13.7 GW nuclear boost by 2032 in the works
New Delhi: India's nuclear power capacity is projected to increase from 8,780 MW to 22,480 MW by 2031-32, driven by the commissioning of eight reactors under construction and 10 more sanctioned projects, Union Minister Jitendra Singh informed the Lok Sabha. At present, India operates 24 nuclear reactors with an installed capacity of 8,780 MW. Additionally, eight reactors with a total capacity of 6,600 MW are under construction. These include 700 MW Pressurised Heavy Water Reactors (PHWRs) such as RAPP-8 and GHAVP-1&2, the 500 MW Prototype Fast Breeder Reactor (PFBR) implemented by BHAVINI, and Light Water Reactors (LWRs) built under foreign cooperation including KKNPP-3&4 and KKNPP-5&6. Ten reactors with a projected capacity of 7,000 MW are at the pre-project activities stage. These include Kaiga 5&6, GHAVP 3&4, Chutka 1&2, and Mahi Banswara 1 to 4—all PHWRs. Upon the progressive completion of these ongoing and sanctioned reactors, the total installed capacity is expected to reach 22,480 MW by 2031-32. "The specific measures outlined to reach this goal involve a multi-faceted approach, leveraging both indigenous development and international collaboration," Singh stated in a written reply. Future expansion includes development of Indigenous Fast Breeder Reactors (FBRs), aligned with India's three-stage nuclear programme designed for efficient utilisation of limited uranium and abundant thorium resources. These efforts will be supported by a closed fuel cycle approach. Deployment of Bharat Small Reactors (BSRs) is also being pursued to decarbonise hard-to-abate industrial sectors. Additionally, plans are in place for the development of Small Modular Reactors (SMRs), including Indian SMRs of different capacities and Indian-designed LWRs. The government has launched a Nuclear Energy Mission with an outlay of ₹20,000 crore to support research and development of SMRs. The plan also includes increasing international cooperation on SMRs and nuclear fuel, along with potential exports of reactors, services, and supplies.
